Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia

被引:7
作者
Heffelfinger, James D. [1 ]
Voetsch, Andrew C. [1 ]
Nakamura, Glenn V. [1 ]
Sullivan, Patrick S. [2 ]
McNaghten, A. D. [1 ]
Huang, Laurence [3 ,4 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA
来源
PLOS ONE | 2009年 / 4卷 / 03期
基金
美国国家卫生研究院;
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS;
D O I
10.1371/journal.pone.0005002
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Discontinuation of Pneumocystis jirovecii Pneumonia Prophylaxis with CD4 Count <200 Cells/μL and Virologic Suppression: A Systematic Review
    Costiniuk, Cecilia T.
    Fergusson, Dean A.
    Doucette, Steve
    Angel, Jonathan B.
    PLOS ONE, 2011, 6 (12):
  • [32] Pneumocystis jirovecii pneumonia in people living with HIV: a review
    Mcdonald, Emily G.
    Afshar, Avideh
    Assiri, Bander
    Boyles, Tom
    Hsu, Jimmy M.
    Khuong, Ninh
    Prosty, Connor
    So, Miranda
    Sohani, Zahra N.
    Butler-Laporte, Guillaume
    Lee, Todd C.
    CLINICAL MICROBIOLOGY REVIEWS, 2024, 37 (01)
  • [33] Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy
    Halani, Sheliza
    Andany, Nisha
    Shah, Rupal
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2020, 192 (43) : E1206 - E1208
  • [34] Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas
    De Vos, Filip Y.
    Gijtenbeek, Johanna M.
    Bleeker-Rovers, Chantal P.
    van Herpen, Carla M.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 85 (03) : 373 - 382
  • [35] Outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients on prophylaxis: Our observation and experience
    Chandola, P.
    Lall, M.
    Sen, S.
    Bharadwaj, R.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2014, 32 (03) : 333 - U186
  • [36] Usefulness of Bronchoscopic Probe-Based Confocal Laser Endomicroscopy in the Diagnosis of Pneumocystis jirovecii Pneumonia
    Shafiek, Hanaa
    Fiorentino, Federico
    Cosio, Borja G.
    Kersul, Ana
    Thiberville, Luc
    Gomez, Cristina
    Riera, Melchor
    Martin, Maria L.
    Martinez, Rocio
    Noguera, Maria A.
    Agusti, Alvar
    Sauleda, Jaume
    RESPIRATION, 2016, 92 (01) : 40 - 47
  • [37] Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis
    Sauvat, Leo
    Denis, Laure
    Nourrisson, Celine
    Poirier, Philippe
    Ruivard, Marc
    Le Guenno, Guillaume
    FRONTIERS IN MEDICINE, 2024, 11
  • [38] Safety of Once-Weekly Dapsone for Pneumocystis jirovecii Pneumonia Prophylaxis in Kidney Transplant Recipients
    Schumacher, Lauren
    Philippart, Olivia
    Carr, Abbey
    Sadler, Catherine J.
    Paluri, Sravanthi
    TRANSPLANT INFECTIOUS DISEASE, 2025,
  • [39] Prophylaxis for Pneumocystis jirovecii pneumonia in a 42-year-old woman undergoing immunosuppressive therapy
    Halani, Sheliza
    Andany, Nisha
    Shah, Rupal
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (01) : E34 - E36
  • [40] Reversible Cystic Lesions of Pneumocystis jirovecii Pneumonia
    Lu, Ching-Lan
    Hung, Chien-Ching
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 185 (06) : E7 - E8